Month: October 2019

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Dear Friend: We wanted to give you an update on the extremely important and successful work that the Institute for Myeloma & Bone Cancer Research (IMBCR) has conducted during the past six months as we continue our groundbreaking research into finding a cure for multiple myeloma and other bone cancers. IMBCR remains the only independent…

There is a very fine balance between being exposed to healthy doses of sunlight and setting yourself up for potentially grave sun damage. The benefits of spending time outdoors to boost your body’s Vitamin D production are being touted relentlessly, but so is the skin cancer risk associated with UV radiation. The role Vitamin D…

Dear Friend: We wanted to give you an update on the extremely important and successful work that the Institute for Myeloma & Bone Cancer Research (IMBCR) has undertaken during the past six months as we continue our groundbreaking research into finding a cure for multiple myeloma and other bone cancers. IMBCR remains the only independent…

7 Day/8 Night Palm Desert Luxury Villa for BNP PARIBAS OPEN TENNIS QFs + Semis + Finals Bid Now

If you’re an Amazon customer, it’s easy to donate to IMBCR automatically, with almost every purchase. Just go to www.smile.amazon.com and follow 2 simple steps. STEP 1: Go to www.smile.amazon.com and enter “Institute for Myeloma & Bone Cancer Research” (NOT imbcr.org) into the “Search for your charity” box. STEP 2: When our name pops up…

Luncheon with the Stars Four Seasons Los Angeles – Sunday, October 22nd 300 South Doheny Drive, Los Angeles, CA 90048 11.30 am to 2.30 pm Click For More Fundraiser Info

Exciting, new approaches to myeloma treatment are now being developed and tested in the clinic We have made continued progress both in our discovery of new treatments for myeloma and ways to monitor the disease. Our work in the research laboratory has uncovered a new approach to myeloma that is now being tested in the…

Sanchez E, Li M, Wang CS, Tang G, Gillespie A, Chen H, Berenson JR Abstract Oprozomib (OPZ or ONYX 0912) is an irreversible, orally administered proteasome inhibitor (PI) and an analog of carfilzomib. We set out to determine the anti-angiogenic effect of OPZ using the choriollantoic membrane/feather bud (CAM/FB) model and its anti-MM effects using…

Berenson A, Vardanyan S, David M, Wang J, Harutyunyan NM, Gottlieb J, Halleluyan R, Spektor TM, Udd KA Eshaghian S, Nassir Y, Eades B, Swift R, Berenson JR Abstract New classes of drugs including the proteasome inhibitors (PI) bortezomib and, more recently, carfilzomib and the immunomodulatory agent lenalidomide have shown improved outcomes for multiple myeloma…